| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
18,400,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Orchard Therapeutics is a holding company. Through its subsidiaries, Co. is a gene therapy company focused on the development of potentially curative gene therapies. Co.'s programs focused on neurodegenerative disorders consist of its commercial program approved in Europe, Libmeldy (OTL-200) for metachromatic leukodystrophy, two clinical proof of concept-stage programs, OTL-203 for mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, and three preclinical programs, OTL-202 for mucopolysaccharidosis type IIIB, OTL-204 for frontotemporal dementia with progranulin mutations and OTL-205 for amyotrophic lateral sclerosis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shah Rajeev M. |
10% Owner |
– – • |
2020-08-10 |
4 |
B |
$4.71 |
$101,174 |
I/I |
21,357 |
9,133,205 |
1.5 |
- |
|
| Shah Rajeev M. |
10% Owner |
– – • |
2020-08-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
9,111,848 |
|
- |
|
| Thomas Frank E |
See Remarks |
• – – |
2020-06-11 |
4 |
OE |
$2.44 |
$24,400 |
D/D |
10,000 |
25,120 |
|
- |
|
| Gaspar Bobby |
See Remarks |
• • – |
2020-03-02 |
4 |
AS |
$13.00 |
$63,973 |
D/D |
(4,921) |
348,319 |
|
- |
|
| Gaspar Bobby |
See Remarks |
• • – |
2020-03-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,921 |
353,240 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – • |
2020-01-02 |
4 |
S |
$13.41 |
$117,378 |
I/I |
(8,753) |
6,122,295 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – • |
2020-01-02 |
4 |
S |
$13.41 |
$265,994 |
I/I |
(19,721) |
6,131,048 |
|
- |
|
| Fmr Corp |
10% Owner |
– – • |
2020-01-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
12,273,064 |
|
- |
|
| Geraghty James A |
Director |
– • – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
44,391 |
|
- |
|
| Beck Joanne T. |
Director |
– • – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,294 |
|
- |
|
| Glaxosmithkline Plc |
Director |
– • • |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
12,455,252 |
|
- |
|
| Gaspar Bobby |
See RemarksOfficer |
• • – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,000 |
|
- |
|
| Gaspar Bobby |
See RemarksOfficer |
• • – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
348,319 |
|
- |
|
| Rowland Charles A Jr |
Director |
– • – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,294 |
|
- |
|
| Rothera Mark |
See RemarksOfficer |
• • – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,000 |
|
- |
|
| Rothera Mark |
See RemarksOfficer |
• • – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
93,796 |
|
- |
|
| Dunoyer Marc |
Director |
– • – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
37,179 |
|
- |
|
| Thomas Frank E |
See RemarksOfficer |
• – – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,120 |
|
- |
|
43 Records found
|
|
Page 2 of 2 |
|
|
